PLUS1
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last: $ 2.34 ◊ 0.00 (0.00%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Lexicon Pharmaceuticals Inc | LXRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.08 | -3.31% | 2.34 | 2.48 | 2.25 | 2.37 | 2.42 | 23:59:47 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 2.12 | 2.48 | 0.36 | 14.52% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 7,199 | 1,777,444 | $ 2.40 | $ 4,257,656 | 1,867,072 | 1.125 - 11.51 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:57:54 | 20 | $ 2.41 | USD |
Lexicon Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 248.68M | 106.27M | $ -120.55M | -1.14 | - | 104.27M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 11.00 | 1.90% |
Lexicon Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 9/10/2019 | 16:54 | Dow Jones News | Lexicon Pharmaceuticals Says It Terminated Sanofi Alliance |
| 9/10/2019 | 16:04 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 9/10/2019 | 16:01 | GlobeNewswire Inc. | Lexicon Pharmaceuticals Announces Termination of Alliance.. |
| 8/30/2019 | 07:00 | GlobeNewswire Inc. | Lexicon Pharmaceuticals To Present At Upcoming Investor.. |
| 8/20/2019 | 17:03 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 8/09/2019 | 07:00 | GlobeNewswire Inc. | Lexicon Pharmaceuticals to Present at Upcoming Investor.. |
| 8/02/2019 | 16:17 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LXRX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.3 | 2.71 | 1.29 | 2.1263 | 5M | 1.04 | 80.00% |
| 1 Month | 1.35 | 2.71 | 1.22 | 1.8863 | 2M | 0.99 | 73.33% |
| 3 Months | 5.96 | 6.72 | 1.125 | 2.0063 | 2M | -3.62 | -60.74% |
| 6 Months | 7.69 | 8.55 | 1.125 | 3.4087 | 1M | -5.35 | -69.57% |
| 1 Year | 10.8 | 11.51 | 1.125 | 4.6266 | 877k | -8.46 | -78.33% |
| 3 Years | 18.56 | 19.62 | 1.125 | 9.8789 | 744k | -16.22 | -87.39% |
| 5 Years | 1.52 | 19.62 | 0.8 | 8.0192 | 922k | 0.82 | 53.95% |
Lexicon Pharmaceuticals Description
| Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising drug targets. Lexicon then designs and develops drugs for these targets, which cover a broad spectrum of therapeutic areas. Following a restructuring in January 2014, Lexicon focused efforts on two drugs: sotagliflozin in diabetes, which is partnered with Sanofi, and Xermelo (telotristat etiprate) in carcinoid syndrome, which is partnered with Ipsen outside the U.S. Early-stage programs include SGLT1 inhibitor LX2761 and neuropathic pain drug LX9211. |
